Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Joshua Rivera, Qi Yan, Saeed Daneshmandi, Romain Lannes, Eriko Katsuta, JeeEun Choi, Prashant Singh, Ahmed Belal, Ronald Alberico, Ian Lund, Megan Schaefer, Hamza Hassan, Sarah Parker, Kenneth C. Anderson, Nikhil C. Munshi, Mehmet Samur, Philip L. McCarthy, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (20): 2392–2405.

https://doi.org/10.1182/blood.2025028963

Published: 2025

Includes: Supplemental data

Journal Articles

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Muhammad Salman Faisal, Nour Nassour, Sean Glenn, Han Yu, Sarah Parker, Hamza Hassan, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7484.

https://doi.org/10.1182/blood-2025-7484

Published: 2025

Journal Articles

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

Zunairah Shah, Ian Lund, Sarah Parker, Kimberly Celotto, Kristina Slemmer, Hailey Battaglia, Megan Schaefer, Yongdong Ouyang, Hamza Hassan, Jens Hillengass

Blood (2025) 146 (Supplement 1): 7532.

https://doi.org/10.1182/blood-2025-7532

Published: 2025

Journal Articles

Genomic determinants and differences of primary and secondary plasma cell leukemia

Mehmet Samur, Hamza Hassan, Qi Yan, Sarah Parker, Prashant Singh, Megan Schaefer, Kristina Slemmer, Kimberly Celotto, Ian Lund, Hailey Battaglia, Annmarie Nowak, Linda Lutgen, Saeed Daneshmandi, Kenan Onel, Philip McCarthy, Nikhil Munshi, Jens Hillengass, Hemn Mohammadpour

Blood (2025) 146 (Supplement 1): 7469.

https://doi.org/10.1182/blood-2025-7469

Published: 2025

Journal Articles

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Blood (2025) 146 (Supplement 1): 827.

https://doi.org/10.1182/blood-2025-827

Published: 2025

Journal Articles

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Blood (2025) 146 (Supplement 1): 825.

https://doi.org/10.1182/blood-2025-825

Published: 2025

Journal Articles

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Blood (2025) 146 (Supplement 1): 824.

https://doi.org/10.1182/blood-2025-824

Published: 2025

Journal Articles

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 5852.

https://doi.org/10.1182/blood-2025-5852

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Alexis Castaneda Puglianini, Gabriel De Avila, Christian Gordillo, Eli Zolotov, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen

Blood (2025) 146 (Supplement 1): 1034.

https://doi.org/10.1182/blood-2025-1034

Published: 2025

Journal Articles

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Janine Joseph, Joseph Tario, Han Yu, Sarah Parker, Ian Lund, Kristina Slemmer, Hailey Battaglia, Megan Schaefer, Kimberly Celotto, Philip McCarthy, Hamza Hassan, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 1411.

https://doi.org/10.1182/blood-2025-1411

Published: 2025

Journal Articles

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling

Ehsan Malek, Megan Herr, James Driscoll, Paul Wallace, Marco Davila, Brian Betts, Shernan Holtan, Hamza Hassan, Theresa Hahn, Han Yu

Blood (2025) 146 (Supplement 1): 3935.

https://doi.org/10.1182/blood-2025-3935

Published: 2025

Journal Articles

Circulating immune profile in patients with amyloidosis

Janine Joseph, Joseph Tario, Han Yu, Philip McCarthy, Hamza Hassan, Sarah Parker, Megan Schaefer, Hailey Battaglia, Hemn Mohammadpour, Jens Hillengass

Blood (2025) 146 (Supplement 1): 5748.

https://doi.org/10.1182/blood-2025-5748

Published: 2025

Journal Articles

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Blood (2025) 146 (Supplement 1): 4069.

https://doi.org/10.1182/blood-2025-4069

Published: 2025

Journal Articles

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 137.

https://doi.org/10.1182/blood-2025-137

Published: 2025

Journal Articles

Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 136.

https://doi.org/10.1182/blood-2025-136

Published: 2025

Journal Articles

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett Reid, Danai Dima, Lauren Peres, Mahmoud Gaballa, Rahul Banerjee, Oren Pasvolsky, Aimaz Afrough, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Masooma Rana, Hitomi Hosoya, Lekha Mikkilineni, Vanna Hovanky, Saurabh Zanwar, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Omar Puglianini, Gabriel De Avila, Eli Zolotov, Evguenia Bhurtel, Ariel Grajales-Cruz, Utkarsh Goel, Aishwarya Sannareddy, Jeries Kort, Raffaella Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Zhuoer Xie, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Leyla Shune, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Saurabh Dahiya, Frederick Locke, David Miklos, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Yi Lin, Krina Patel, Doris Hansen, Surbhi Sidana

Blood (2025) 146 (Supplement 1): 134.

https://doi.org/10.1182/blood-2025-134

Published: 2025

Journal Articles

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 719.

https://doi.org/10.1182/blood-2025-719

Published: 2025

Journal Articles

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 717.

https://doi.org/10.1182/blood-2025-717

Published: 2025

Journal Articles

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Danai Dima, Lauren Peres, Leyla Shune, Christelle Leitzinger, Brett Reid, Andrew Portuguese, Raffaella Cassano Cassano, Rahul Banerjee, Nilesh Kalariya, Oren Pasvolsky, Mahmoud Gaballa, Zachary Hunzeker, Christen Dillard, Hitomi Hosoya, Lekha Mikkilineni, Rebecca Gonzalez, Ariel Grajales-Cruz, Omar Alexis Castaneda Puglianini, Taiga Nishihori, Charlotte Wagner, Christopher Cahoon, Douglas Sborov, Evguenia Bhurtel, Jeries Kort, Marcus Geer, Sneha Purvey, Christopher Ferreri, Cindy Varga, Shebli Atrash, Peter Voorhees, Utkarsh Goel, Jack Khouri, Shahzad Raza, Faiz Anwer, Aimaz Afrough, Aishwarya Sannareddy, Larry Anderson, Hamza Hassan, Megan Herr, Ran Reshef, Christian Gordillo, Eli Zolotov, Noa Biran, James Davis, Kimberly Green, Saurabh Zanwar, Yi Lin, Luciano Costa, Susan Bal, Shonali Midha, Omar Nadeem, Melissa Alsina, Rachid Baz, Kenneth Shain, Frederick Locke, Shaji Kumar, Krina Patel, Surbhi Sidana, Doris Hansen

Blood (2025) 146 (Supplement 1): 4000.

https://doi.org/10.1182/blood-2025-4000

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma

Mutations landscape of relapsed refractory multiple myeloma patients prior to anti-BCMA treatment

Real-world outcomes with elotuzumab, lenalidomide, and dexamethasone in patients progressing on lenalidomide maintenance therapy: A single-center retrospective analysis

Genomic determinants and differences of primary and secondary plasma cell leukemia

Safety and efficacy of talquetamab in patients with relapsed and refractory multiple myeloma (RRMM) with and without renal impairment (RI)

Talquetamab outcomes in relapsed/refractory myeloma with extramedullary and paraskeletal soft tissue plasmacytomas

Outcomes of bispecific T-cell engagers in MM patients with central nervous system (CNS) involvement

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Peripheral blood and bone marrow immune profiles are strongly correlated in patients with plasma cell disorders

Accelerated immune aging after induction therapy in multiple myeloma revealed by donor-referenced immune age modeling

Circulating immune profile in patients with amyloidosis

Identifying high-risk profiles and adverse prognoses in relapsed/refractory multiple myeloma treated with bispecific antibodies: A real-world analysis of 943 treatment initiations

Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium

Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Real-world outcomes of immune effector cell-associated hemophagocytic syndrome (IEC-HS) following ide-cel and cilta-cel therapy in relapsed/refractory multiple myeloma

Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM)

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only